A Non-Randomized Multicenter Phase I/II Study Of Active Specific Immunotherapy In Patients With Stage II and Stage III Colon Cancer
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy combined with leucovorin and fluorouracil in treating patients who have undergone surgery to completely remove stage II or stage III colon cancer.
A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether keyhole limpet hemocyanin is more effective than doxorubicin for bladder cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of keyhole limpet hemocyanin with that of doxorubicin in treating patients who have bladder cancer that has not responded to BCG or in those patients who cannot tolerate BCG.
100 Clinical Results associated with Intracel Corp.
0 Patents (Medical) associated with Intracel Corp.
01 Jan 2001·Food and drug law journalQ4 · MEDICINE
WLF and the two-click rule: the First Amendment inequity of the Food and Drug Administration's regulation of off-label drug use information on the Internet.
01 Jan 2000·Food and drug law journalQ4 · MEDICINE
Global harmonization of regulatory requirements for premarket approval of autologous cell therapies.
01 Jul 1998·The Journal of urology
RE: EDITORIAL: DATA INTERPRETATION AND INTEGRATION OF NEW TESTS INTO CLINICAL PRACTICE
Letter
Author: Butman, Bryan T. ; Hanna, Michael G.
100 Deals associated with Intracel Corp.
100 Translational Medicine associated with Intracel Corp.